Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study

Objective To evaluate the effect of depot medroxyprogesterone acetate (DMPA) in protecting against epithelial ovarian cancer (EOC) and to evaluate factors associated with the risk of EOC. Design A multicentre, case-control study. Setting Twelve hospitals located across Thailand. Population Three hun...

Full description

Saved in:
Bibliographic Details
Main Authors: Wilailak S., Vipupinyo C., Suraseranivong V., Chotivanich K., Kietpeerakool C., Tanapat Y., Therasakvichya S., Hamontri S., Linasmita V., Bunyapipat S., Chindavijak S., Ittiwisavakul K., Khemapech N., Suekwattana P., Thanapprapasr D., Lumbiganon P.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84859717358&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/42847
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-42847
record_format dspace
spelling th-cmuir.6653943832-428472017-09-28T06:40:53Z Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study Wilailak S. Vipupinyo C. Suraseranivong V. Chotivanich K. Kietpeerakool C. Tanapat Y. Therasakvichya S. Hamontri S. Linasmita V. Bunyapipat S. Chindavijak S. Ittiwisavakul K. Khemapech N. Suekwattana P. Thanapprapasr D. Lumbiganon P. Objective To evaluate the effect of depot medroxyprogesterone acetate (DMPA) in protecting against epithelial ovarian cancer (EOC) and to evaluate factors associated with the risk of EOC. Design A multicentre, case-control study. Setting Twelve hospitals located across Thailand. Population Three hundred and thirty patients with EOC ('cases') and 982 matched controls were recruited from the 12 hospitals. Cases were newly diagnosed patients with EOC, demonstrated pathologically. Controls were age-matched patients admitted to different wards in the same hospital. Methods Cases and controls were interviewed by trained interviewers using a standardised pre-tested questionnaire. The factors associated with EOC were evaluated using univariate and multivariate analyses. Main outcome measures The odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relationship between DMPA and EOC. Results The use of DMPA was found to be associated with a 39% reduction in the risk of EOC with an OR of 0.61 and a 95% CI of 0.44-0.85 (P = 0.002). A significant risk reduction (83%) was observed when the duration of DMPA use was > 3 years (OR 0.17; 95% CI 0.07-0.39; P < 0.001). Other factors associated with a reduced risk of EOC were the use of combined oral contraceptive pills and breastfeeding. A factor associated with an increased risk of EOC was a family history of gynaecological cancer. Conclusions The results suggest that DMPA may have a protective effect against EOC. If this effect is real, then it represents an important non-contraceptive benefit of DMPA. © 2012 RCOG. 2017-09-28T06:40:53Z 2017-09-28T06:40:53Z 2012-05-01 Journal 14700328 2-s2.0-84859717358 10.1111/j.1471-0528.2012.03298.x https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84859717358&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/42847
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description Objective To evaluate the effect of depot medroxyprogesterone acetate (DMPA) in protecting against epithelial ovarian cancer (EOC) and to evaluate factors associated with the risk of EOC. Design A multicentre, case-control study. Setting Twelve hospitals located across Thailand. Population Three hundred and thirty patients with EOC ('cases') and 982 matched controls were recruited from the 12 hospitals. Cases were newly diagnosed patients with EOC, demonstrated pathologically. Controls were age-matched patients admitted to different wards in the same hospital. Methods Cases and controls were interviewed by trained interviewers using a standardised pre-tested questionnaire. The factors associated with EOC were evaluated using univariate and multivariate analyses. Main outcome measures The odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relationship between DMPA and EOC. Results The use of DMPA was found to be associated with a 39% reduction in the risk of EOC with an OR of 0.61 and a 95% CI of 0.44-0.85 (P = 0.002). A significant risk reduction (83%) was observed when the duration of DMPA use was > 3 years (OR 0.17; 95% CI 0.07-0.39; P < 0.001). Other factors associated with a reduced risk of EOC were the use of combined oral contraceptive pills and breastfeeding. A factor associated with an increased risk of EOC was a family history of gynaecological cancer. Conclusions The results suggest that DMPA may have a protective effect against EOC. If this effect is real, then it represents an important non-contraceptive benefit of DMPA. © 2012 RCOG.
format Journal
author Wilailak S.
Vipupinyo C.
Suraseranivong V.
Chotivanich K.
Kietpeerakool C.
Tanapat Y.
Therasakvichya S.
Hamontri S.
Linasmita V.
Bunyapipat S.
Chindavijak S.
Ittiwisavakul K.
Khemapech N.
Suekwattana P.
Thanapprapasr D.
Lumbiganon P.
spellingShingle Wilailak S.
Vipupinyo C.
Suraseranivong V.
Chotivanich K.
Kietpeerakool C.
Tanapat Y.
Therasakvichya S.
Hamontri S.
Linasmita V.
Bunyapipat S.
Chindavijak S.
Ittiwisavakul K.
Khemapech N.
Suekwattana P.
Thanapprapasr D.
Lumbiganon P.
Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
author_facet Wilailak S.
Vipupinyo C.
Suraseranivong V.
Chotivanich K.
Kietpeerakool C.
Tanapat Y.
Therasakvichya S.
Hamontri S.
Linasmita V.
Bunyapipat S.
Chindavijak S.
Ittiwisavakul K.
Khemapech N.
Suekwattana P.
Thanapprapasr D.
Lumbiganon P.
author_sort Wilailak S.
title Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
title_short Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
title_full Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
title_fullStr Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
title_full_unstemmed Depot medroxyprogesterone acetate and epithelial ovarian cancer: A multicentre case-control study
title_sort depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84859717358&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/42847
_version_ 1681422267086536704